medigraphic.com
Revista Médica Sinergia

2022, Número 02

<< Anterior Siguiente >>

Revista Médica Sinergia 2022; 7 (02)


Manifestaciones cutáneas por infección SARS-COV-2 confirmado o sospechoso en diferentes rangos de edades

Campos BD, Sojo PJ, Vargas ÁA

Idioma: Español
Referencias bibliográficas: 46
Paginas:
Archivo PDF: 499.29 Kb.


RESUMEN

El SARS-CoV-2 es un nuevo tipo de coronavirus, que apareció a finales de 2019 en Wuhan, China y luego se extendió por todo el mundo. Declarándose pandemia el 11 de marzo 2020. Diversos hallazgos dermatológicos de este virus son inespecíficos. El espectro clínico de COVID-19 se define mejor día a día, incluso presentando nuevos síntomas. Varios estudios indican que en esta enfermedad infecciosa han aparecido diferentes manifestaciones cutáneas. En esta revisión se presenta el conocimiento actual sobre las lesiones cutáneas asociadas a COVID-19, basándose en las características clínicas, fases de la enfermedad, evolución y manejo terapéutico de cada de ellas, intentando dar una visión general de los posibles mecanismos patogénicos con sus factores contribuyentes. Aún se desconoce la prevalencia real de las lesiones cutáneas asociadas a COVID-19; actualmente se están incluyendo nuevos estudios fundamentales para ampliar nuestro conocimiento sobre estas manifestaciones cutáneas atípicas. Se considera que las lesiones cutáneas pueden ser importantes indicadores de sospecha diagnóstica a considerar en casos sopechosos de COVID19.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Ministerio de Salud, LS-VS-001. Lineamientos Nacionales para la Vigilancia de la enfermedad COVID-19. Vigésima segunda edición. 27 de septiembre 2021.

  2. Organización Mundial de la Salud. Coronavirus disease 2019 (COVID-19) Situation Report. Accessed on March 27,2020. https://apps.who.int/iris/bitstream/handle/10665/331865/nCoVsitrep23Apr2020-eng.pdf

  3. Centers for Disease Control and Prevention. 2019 Novel coronavirus, Wuhan, China. Information for Healthcare Professionals. (Accessed on February 14, 2020). https://www.cdc.gov/coronavirus/2019-nCoV/hcp/index.html

  4. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol. 2020.https://doi.org/10.1111/jdv.16387

  5. Marzano AV, Cassano N, Genovese G, Moltrasio C, Vena GA. Cutaneous manifestations in patients with COVID‐19: a preliminary review of an emerging issue. BJD. 2020 Jun 1; 183 (3): 431- 42. https://onlinelibrary.wiley.com/doi/10.1111/bj.19264

  6. Guan WJ, Ni ZY, Hu Y et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382: 1708– 20. https://www.nejm.org/doi/10.1056/NEJMoa2002032

  7. Hoehl S, Rabenau H, Berger A et al. Evidence of SARS-CoV-2 infection in returning travelers from Wuhan, China. N Engl J Med 2020; 382: 1278– 80. https://www.nejm.org/doi/10.1056/NEJMc2001899

  8. Joob B, Wiwanitkit V. COVID-19 can present with a rash and be mistaken for dengue. J Am Acad Dermatol 2020; 82: e177.https://pubmed.ncbi.nlm.nih.gov/32213305/

  9. Kamali Aghdam M, Jafari N, Eftekhari K. Novel coronavirus in a 15-day-old neonate with clinical signs of sepsis, a case report. Infect Dis (Lond) 2020; 52: 427– 9. https://www.tandfonline.com/doi/full/10.1080/23744235.2020.1747634

  10. Giovanni Genovesea, Chiara Moltrasioa, Emilio Bertia, Angelo Valerio Marzanoa. Skin Manifestations Associated with COVID-19: Current Knowledge and Future Perspectives. Dermatology 2021;237:1–12. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7801998/

  11. Galván Casas C, Català A, Carretero Hernández G, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol 2020. https://pubmed.ncbi.nlm.nih.gov/32348545/

  12. Hedou M, Carsuzaa F, Chary E et al. Comment on ‘Cutaneous manifestations in COVID-19: a first perspective’ by Recalcati S. J Eur Acad Dermatol Venereol 2020; in press. https://onlinelibrary.wiley.com/doi/10.1111/jdv.16519

  13. Mahé A, Birckel E, Krieger S et al. A distinctive skin rash associated with coronavirus disease 2019? J Eur Acad Dermatol Venereol 2020; 34: e246– 7. https://onlinelibrary.wiley.com/doi/10.1111/jdv.16471

  14. Gianotti R, Veraldi S, Recalcati S et al. Cutaneous clinico-pathological findings in three COVID-19-positive patients observed in the metropolitan area of Milan, Italy. Acta Derm Venereol 2020; 100: adv00124.https://pubmed.ncbi.nlm.nih.gov/32315073/

  15. Recalcati S, Barbagallo T, Frasin LA et al. Acral cutaneous lesions in the time of COVID-19. J Eur Acad Dermatol Venereol 2020; in press. https://onlinelibrary.wiley.com/doi/10.1111/jdv.16533

  16. Bouaziz JD, Duong T, Jachiet M, et al. Vascular skin symptoms in COVID-19: a French observational study. J Eur Acad Dermatol Venereol 2020. https://doi.org/10.1111/jdv.16544

  17. Tammaro A, Adebanjo GAR, Parisella FR et al. Cutaneous manifestations in COVID-19: the experiences of Barcelona and Rome. J Eur Acad Dermatol Venereol 2020; in press https://doi.org/10.1111/jdv.16530

  18. Manalo I.F, Smith M.K., Cheeley J. Jacobs R. A dermatologic manifestation of COVID-19: transient livedo reticularis. J Am Acad Dermatol. 2020; 83: 700.https://pubmed.ncbi.nlm.nih.gov/32283229/

  19. Magro C, Mulvey JJ, Berlin D et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res 2020; in press. https://doi.org/10.1016/j.trsl.2020.04.007

  20. Henry D, Ackerman M, Sancelme E et al. Urticarial eruption in COVID-19 infection. J Eur Acad Dermatol Venereol 2020; 34: e244– 5. https://pubmed.ncbi.nlm.nih.gov/32294273/

  21. Gianotti R, Veraldi S, Recalcati S, Cusini M, Ghislanzoni M, Boggio F, et al. Cutaneous Clinico-Pathological Findings in three COVID-19-Positive Patients Observed in the Metropolitan Area of Milan, Italy. Acta Derm Venereol. 2020 Apr;100(8):adv00124–2. https://pubmed.ncbi.nlm.nih.gov/32315073/

  22. Marzano AV, Genovese G, Fabbrocini G et al. Varicella-like exanthem as a specific COVID-19-associated skin manifestation: multicenter case series of 22 patients. J Am Acad Dermatol 2020; 83: 280– 5. https://pubmed.ncbi.nlm.nih.gov/32305439/

  23. Estébanez A, Pérez-Santiago L, Silva E et al. Cutaneous manifestations in COVID-19: a new contribution. J Eur Acad Dermatol Venereol 2020; 34: e250– 1. https://pubmed.ncbi.nlm.nih.gov/32294264/

  24. Sanchez A, Sohier P, Benghanem S et al. Digitate papulosquamous eruption associated with severe acute respiratory syndrome coronavirus 2 infection. JAMA Dermatol 2020; in press. https://jamanetwork.com/journals/jamadermatology/fullarticle/2765613

  25. Gisondi P, Piaserico S, Conti A et al. Dermatologists and SARS-CoV-2: the impact of the pandemic on daily practice. J Eur Acad Dermatol Venereol 2020; 34: 1196– 201. https://pubmed.ncbi.nlm.nih.gov/32320091/

  26. Marrouche N, Grattan C. Childhood urticaria. Curr Opin Allergy Clin Immunol 2012; 12: 485– 90. https://pubmed.ncbi.nlm.nih.gov/22825024/

  27. Freeman EE, McMahon DE, Lipoff JB, et al. Pernio-like skin lesions associated with COVID-19: a case series of 318 patients from 8 countries. J Am Acad Dermatol 2020; S0190-9622(20)30984-30991. https://www.jaad.org/article/S0190-9622(20)30984-1/fulltext

  28. Shanshal M. Low-dose systemic steroids, an emerging therapeutic option for COVID19-related urticaria. J Dermatolog Treat. 2020 Jul;16:1–2. https://pubmed.ncbi.nlm.nih.gov/32649228/

  29. Herman A, Peeters C, Verroken A, Tromme I, Tennstedt D, Marot L et al. Evaluation of Chilblains as a Manifestation of the COVID-19 Pandemic. JAMA Dermatol. 2020 Sep 1; 156 (9): 998-1003. https://jamanetwork.com/journals/jamadermatology/fullarticle/2767774

  30. Najarian DJ. Morbilliform exanthem associated with COVID-19. JAAD Case Rep. 2020 Apr;6(6):493–4. https://pubmed.ncbi.nlm.nih.gov/32313826/

  31. Genovese G, Colonna C, Marzano AV. Varicella-like exanthem associated with COVID-19 in an 8-year-old girl: A diagnostic clue? Pediatr Dermatol. 2020 May;37(3):435–6. https://pubmed.ncbi.nlm.nih.gov/32315079/

  32. Fernandez-Nieto D, Ortega-Quijano D, Jimenez-Cauhe J, Burgos-Blasco P, de Perosanz-Lobo D, Suarez-Valle A, et al. Clinical and histological characterization of vesicular COVID-19 rashes: a prospective study in a tertiary care hospital. Clin Exp Dermatol. 2020 May;45(7):872–5. https://pubmed.ncbi.nlm.nih.gov/32384180/

  33. Fernandez-Nieto D., Jimenez-Cauhe J., Suarez-Valle A., Moreno-Arrones O.M., Saceda-Corralo D., Arana-Raja A. Characterization of Acute Acro-Ischemic Lesions in Non-Hospitalized Patients: A Case Series of 132 Patients During the COVID-19 Outbreak. J Am Acad Dermatol. 2020;S0190–9622. https://pubmed.ncbi.nlm.nih.gov/32339703/

  34. Piccolo V., Neri I., Filippeschi C. et al. Chilblain-like lesions during COVID-19 epidemic: a preliminary study on 63 patients. ([e-pub ahead of print]. J Eur Acad Dermatol Venereol). https://onlinelibrary.wiley.com/doi/10.1111/jdv.16526

  35. Recalcati S, Barbagallo T, Frasin LA et al. Acral cutaneous lesions in the time of COVID-19. J Eur Acad Dermatol Venereol 2020; in press. https://doi.org/10.1111/jdv.16533

  36. Cappel J.A., Wetter D.A. Clinical characteristics, etiologic associations, laboratory findings, treatment, and proposal of diagnostic criteria of pernio (chilblains) in a series of 104 patients at Mayo Clinic, 2000 to 2011. Mayo Clin Proc. 2014; 89: 207-215. https://pubmed.ncbi.nlm.nih.gov/24485134/

  37. Monte Serrano J, Cruañes Monferrer J, García-Gil MF. Lesiones cutáneas acro-isquémicas durante la epidemia COVID-19. Semergen. 2020 Aug; 46 Suppl 1:103-105. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7205664/

  38. Zhang Y, Cao W, Xiao M, et al. Clinical and coagulation characteristics in 7 patients with critical COVID-2019 pneumonia and acro-ischemia [in Chinese]. Zhonghua Xue Ye Xue Za Zhi. 2020;41(4):302-307. https://pubmed.ncbi.nlm.nih.gov/32447934/

  39. Mazzotta F.;Troccoli T.;Bonifazi E.; A new vasculitis at the time of COVID-19. Eur J Pediatr Dermatol. [Internet]. [Consultado 22 Abr 2020]. Disponible en: https://www.ejpd.com/images/nuova-vasculite-covid-ENG.pdf

  40. Mazzotta F, Troccoli T. Acute acro-ischemia in the child at the time of COVID-19. Eur J Pediatr Dermatol. 2020;30(2):71–4. https://www.ejpd.com/journal/index.php/EJPD/article/view/2102.

  41. Romaní J., Baselga E., Mitjà O., Riera-Martí N., Garbayo P., Vicente A. Chilblain and acral purpuric lesions in Spain during COVID confinement: Retrospective analysis of 12 cases. Actas Dermosifiliogr. 2020 doi: 10.1016/j.ad.2020.04.002. https://pubmed.ncbi.nlm.nih.gov/32402369/.

  42. García-Gil MF, Monte Serrano J, García García M, Barra Borao V, Matovelle Ochoa C, Ramirez-Lluch M et al. Acral purpuric lesions associated with coagulation disorders during the COVID-19 pandemic. Int J Dermatol. 2020 Sep; 59 (9):1151-2. https://onlinelibrary.wiley.com/doi/10.1111/ijd.15041.

  43. Bosch-Amate X, Giavedoni P, Podlipnik S, Andreu-Febrer C, Sanz-Beltran J, GarciaHerrera A, et al. Retiform purpura as a dermatological sign of coronavirus disease 2019 (COVID-19) coagulopathy. J Eur Acad Dermatol Venereol. 2020 Oct;34(10):e548–9.https://pubmed.ncbi.nlm.nih.gov/32491234/

  44. Karaca Z, Yayli S, Çalışkan O. A unilateral purpuric rash in a patient with COVID-19 infection. Dermatol Ther (Heidelb). 2020 Jul; 33(4):e13798. https://pubmed.ncbi.nlm.nih.gov/32530130/

  45. F. Amatore, N. Macagno, M. Mailhe, B. Demarez, C. Gaudy-Marqueste, J.J. Grob, et al. SARS-CoV-2 infection presenting as a febrile rash. J Eur Acad Dermatol Venereol., 34 (2020), pp. e304-e306.https://onlinelibrary.wiley.com/doi/10.1111/jdv.16528

  46. P. Gisondi, S. Plaserico, C. Bordin, M. Alaibac, G.Girolomoni, L. Naldi. Cutaneous manifestations of SARS COV 2 infection:a clinical update. JEADV. 2020, 34, 2499-2505. https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.16774




2020     |     www.medigraphic.com